Evidence map›Paper›PMID 34299349›Full record

ReviewInternational journal of molecular sciences2021

Retinoids as Chemo-Preventive and Molecular-Targeted Anti-Cancer Therapies.

Victoria O Hunsu, Caroline O B Facey, Jeremy Z Fields, Bruce M Boman

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Cetyl All-International journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Victoria O HunsuCenter for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, Newark, DE 19713, USA.
Caroline O B FaceyCenter for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, Newark, DE 19713, USA.
Jeremy Z FieldsCA*TX Inc., Princeton, NJ 08540, USA.
Bruce M BomanCenter for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, Newark, DE 19713, USA.
University of Delaware · USCenter for Cancer Research · US

Funding

Lisa Dean Moseley Foundation 2018
6 · The paper itself

Abstract

Retinoic acid (RA) agents possess anti-tumor activity through their ability to induce cellular differentiation. However, retinoids have not yet been translated into effective systemic treatments for most solid tumors. RA signaling is mediated by the following two nuclear retinoic receptor subtypes: the retinoic acid receptor (RAR) and the retinoic X receptor (RXR), and their isoforms. The identification of mutations in retinoid receptors and other RA signaling pathway genes in human cancers offers opportunities for target discovery, drug design, and personalized medicine for distinct molecular retinoid subtypes. For example, chromosomal translocation involving

Indexed as

AnimalsAntineoplastic AgentsColorectal NeoplasmsHumansMolecular Targeted TherapyReceptors, Retinoic AcidRetinoidsSignal TransductionTretinoinAntineoplastic AgentsReceptors, Retinoic AcidRetinoidsTretinoinadenomatous polyposis colialdehyde dehydrogenasecancer stem cellsmolecular targeted therapiesretinoic acid

Identifiers

PMID34299349
PMCPMC8304138
OpenAlexW3186822316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.